PLXNA2 (Plexin A2) encodes a member of the plexin family of transmembrane receptors for semaphorins, playing critical roles in neural development, circuit formation, and synaptic plasticity. Plexin A2 is essential for axonal guidance during development and continues to regulate synaptic structure and function in the adult brain. Dysregulation of PLXNA2 has been implicated in neurodegenerative diseases, particularly Alzheimer's disease, as well as neurodevelopmental disorders including autism spectrum disorder (ASD) and schizophrenia.
¶ Gene Structure and Expression
The PLXNA2 gene spans approximately 127 kb on chromosome 1q23.3 and consists of 33 exons encoding a 2,034 amino acid transmembrane receptor protein with a molecular weight of approximately 220 kDa.
PLXNA2 exhibits high expression in:
- Cerebral cortex — particularly layer II/III pyramidal neurons
- Hippocampus — CA1-CA3 regions and dentate gyrus granule cells
- Cerebellum — Purkinje cells and granule cells
- Olfactory bulb — mitral and tufted cells
- Thalamus — relay neurons
- Substantia nigra — dopaminergic neurons
Expression peaks during embryonic development and early postnatal periods, with sustained expression in adulthood particularly in regions undergoing continuous plasticity.
¶ Protein Structure and Function
¶ Domain Architecture
Plexin A2 contains:
- Extracellular domain — Sema domain (semaphorin binding), PSI domains (plexin-semaphorin-integrin), IPT/TIG domains (immunoglobulin-like)
- Transmembrane domain — Single-pass membrane anchor
- Cytoplasmic domain — Plexin homology (PH) domain with GTPase-activating protein (GAP) activity for R-Ras and Rap GTPases
Plexin A2 functions as the primary receptor for Class 3 semaphorins (SEMA3A, SEMA3B, SEMA3C, SEMA3F). Binding induces receptor dimerization and activation of downstream signaling cascades:
- Axonal repulsion — SEMA3A binding to PLXNA2 triggers growth cone collapse through RhoA/ROCK-dependent cytoskeletal remodeling
- Synaptic scaling — PLXNA2 modulates AMPA receptor trafficking via Rap GAP activity
- Dendritic arborization — Regulates dendritic branching complexity through R-Ras inactivation
PLXNA2 forms complexes with:
- NRP1 (Neuropilin 1) — Primary co-receptor for SEMA3A/F
- NRP2 (Neuropilin 2) — Co-receptor for SEMA3C/F
- Plexin A1 — Heterodimeric receptor complexes
- Plexin A4 — Coordination in sensory neuron guidance
PLXNA2 is implicated in Alzheimer's disease through multiple mechanisms:
Synaptic Dysfunction:
- PLXNA2-mediated signaling regulates dendritic spine morphology and synaptic plasticity
- Amyloid-beta oligomers disrupt SEMA3A/PLXNA2 signaling, leading to synaptic loss
- Altered PLXNA2 expression correlates with cognitive decline in AD patients
Neuronal Circuit Alterations:
- SEMA3A/PLXNA2 dysregulation contributes to hippocampal circuit dysfunction
- Implicated in entorhinal cortex-to-hippocampal connectivity deficits
- May influence tau pathology propagation along neuronal circuits
Genetic Evidence:
- GWAS studies have identified PLXNA2 variants associated with late-onset AD risk
- Expression quantitative trait loci (eQTLs) in PLXNA2 correlate with AD severity
PLXNA2 is one of the most consistently implicated genes in ASD:
Synaptogenesis Defects:
- Critical for excitatory synapse formation and function
- SEMA3A/PLXNA2 signaling guides postsynaptic specializations
- Disrupted signaling leads to abnormal cortical circuit formation
Neurodevelopmental Evidence:
- De novo missense mutations in PLXNA2 identified in ASD probands
- Mouse models with Plxna2 knockdown exhibit social deficit behaviors
- Altered PLXNA2 expression in postmortem ASD brain tissue
- PLXNA2 variants associated with schizophrenia risk in genome-wide studies
- Dysregulated semaphorin signaling in prefrontal cortex of schizophrenia patients
- Implicated in GABAergic interneuron migration and circuit formation
- Intellectual disability — Rare loss-of-function variants
- Epilepsy — Altered neuronal excitability through disrupted circuit formation
- Multiple sclerosis — Implicated in axonal regeneration failure
Amyloid-beta (Aβ) peptide interferes with PLXNA2 signaling through:
- Direct binding to the Sema domain, blocking semaphorin ligand interaction
- Activation of aberrant downstream signaling cascades
- Induction of PLXNA2 internalization and degradation
- Disruption of actin cytoskeleton dynamics required for synaptic stability
PLXNA2 may influence tau pathology through:
- Regulation of microtubule stability via Rho GTPase signaling
- Modulation of axonal transport efficiency
- Potential for tau propagation through connected neuronal networks
Microglial activation states affect PLXNA2 expression:
- Pro-inflammatory cytokines (IL-1β, TNF-α) downregulate PLXNA2
- Impaired regenerative signaling in chronic neuroinflammation
- SEMA3A antagonists — Blocking excessive SEMA3A signaling to prevent synaptic loss
- Plexin activation mimetics — Promoting neuroprotective signaling
- GAP domain modulators — Targeting downstream GTPase signaling
- AAV-mediated PLXNA2 overexpression to restore synaptic plasticity
- CRISPR-based correction of pathogenic variants in ASD
- Targeting specific neuronal populations using cell-type promoters
- PLXNA2 expression in CSF as a synaptic integrity marker
- Genetic variants as risk stratification biomarkers
- Soluble PLXNA2 as a treatment response biomarker
PLXNA2 interacts with:
- NRP1/NRP2 — Semaphorin co-receptors
- PLXNA1/PLXNA3/PLXNA4 — Plexin family members
- RND1/RND3 — Rho GTPase family
- MST1 — Hippo pathway kinase
- FAK — Focal adhesion kinase
- SRC — Proto-oncogene tyrosine-protein kinase
Key downstream pathways:
- RhoA/ROCK — Cytoskeletal remodeling
- Rap/R-Ras GAP — Synaptic plasticity modulation
- PI3K/Akt — Cell survival signaling
- MAPK/ERK — Growth and differentiation
- Plxna2 knockout — Exhibits axonal guidance defects, impaired hippocampal plasticity
- Conditional knockout — Synaptic dysfunction and memory deficits
- Humanized knock-in — Modeling ASD-associated missense variants
- Morpholino knockdown demonstrates developmental defects in neural circuit formation
- NGS panels for neurodevelopmental disorders include PLXNA2
- Copy number variations (CNVs) involving PLXNA2 identified in patients
- PLXNA2 genotype may influence response to SEMA3A-targeting therapeutics
- Variants affecting drug metabolism pathways
- Structural biology — Cryo-EM studies of Plexin-Semaphorin complexes
- Single-cell analysis — Cell-type specific PLXNA2 expression patterns
- Circuit mapping — Functional connectivity changes with PLXNA2 dysregulation
- Therapeutic screening — High-throughput small molecule discovery
- Mechanisms of PLXNA2 dysfunction in sporadic AD
- Cell-type specific vulnerability patterns
- Long-term effects of therapeutic modulation